TTP 22

• CAT Number: I003181
• CAS Number: 329907-28-0
• Molecular Formula: C16H14N2O2S2
• Molecular Weight: 330.4
• Purity: ≥95%
• Target: CK2
• Solubility: DMSO: ≥ 51 mg/mL
• Storage: Store at -20°C
• IC50: 0.1 uM
• InChI: InChI=1S/C16H14N2O2S2/c1-10-2-4-11(5-3-10)12-8-22-16-14(12)15(17-9-18-16)21-7-6-13(19)20/h2-5,8-9H,6-7H2,1H3,(H,19,20)
• InChIKey: RAOULLCLLOGTDA-UHFFFAOYSA-N
• SMILES: CC(C=C1)=CC=C1C2=CSC3=NC=NC(SCCC(O)=O)=C32

TTP 22 (CAT: I003181) is a small molecule inhibitor that primarily targets casein kinase 2 (CK2), also known as protein kinase CK2. CK2 is a serine/threonine kinase that is involved in various cellular processes, including cell growth, proliferation, and survival. TTP 22 selectively inhibits CK2 activity, leading to modulation of downstream signaling pathways. It has been investigated for its potential therapeutic applications in cancer, as CK2 is often dysregulated in cancer cells and contributes to tumor growth and survival.

Reference

1:Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK)..Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622. PMID: 27998961 2:Tristetraprolin regulation of interleukin-22 production. Härdle L, Bachmann M, Bollmann F, Pautz A, Schmid T, Eberhardt W, Kleinert H, Pfeilschifter J, Mühl H.Sci Rep. 2015 Oct 21;5:15112. doi: 10.1038/srep15112. Erratum in: Sci Rep. 2015;5:17160. PMID: 26486958 Free PMC Article3:Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Bennett CL, Jacob S, Dunn BL, Georgantopoulos P, Zheng XL, Kwaan HC, McKoy JM, Magwood JS, Qureshi ZP, Bandarenko N, Winters JL, Raife TJ, Carey PM, Sarode R, Kiss JE, Danielson C, Ortel TL, Clark WF, Ablin RJ, Rock G, Matsumoto M, Fujimura Y.Br J Haematol. 2013 Jun;161(6):896-8. doi: 10.1111/bjh.12303. Epub 2013 Mar 27. No abstract available. PMID: 23530950 Free PMC Article4:Response to plasmapheresis in myasthenia gravis patients: 22 cases report. Yazdi MF, Baghianimoghadam M, Nazmiyeh H, Ahmadabadi AD, Adabi MA.Rom J Intern Med. 2012 Jul-Sep;50(3):245-7. PMID: 23330293 5:Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura. Langer F, Bergmann F, Budde U, Hegewisch-Becker S, Hossfeld DK.Br J Haematol. 2002 Jul;118(1):271-4. PMID: 12100160 6:[Thrombocytopenic thrombotic purpura. Retrospective study of 22 consecutive occurrences in 16 patients]. Blanco A, Palacio C, López A, Acebedo G, Castellá D, Juliá A.Med Clin (Barc). 1998 Oct 3;111(10):385-8. Spanish. PMID: 9833242 7:[Clinical demonstrations: 1. Renal tubular acidosis; 2. Breast neoplasm with bone metastases in a man; 3. Thrombotic thrombocytopenic purpura; 4. Precocious eclampsia in a 22 years old primipara]. Weber J.Schweiz Med Wochenschr. 1977 Dec 10;107(49):1808-19. French. PMID: 563099